Aenco HealthTech Partner — Aptorum Group’s Latest Announcement on SACT-1 for Neuroblastoma and ALS-4 for Staphylococcus Aureus infections
Dear Aenco Communities,
The Aenco Team is thrilled to share with you the latest press release by our HealthTech partner
Dear Investors and Friends,
I would like to take this opportunity and new year to provide you with an update of Aptorum Group [Nasdaq: APM]. This year 2020 is proving to be an exciting year for Aptorum Group, primarily as we are targeting to transform from a preclinical stage company into a full fledged clinical stage biopharmaceutical company driven by our three major platforms: Smart-ActTM drug repurposing platform for orphan diseases, Acticule infectious diseases platform and Claves microbiome based metabolic diseases platform.
In particular, at the same time of this communication, we have provided a business wire update globally on our two most advanced assets, SACT-1 for Neuroblastoma and ALS-4 for Staphylococcus Aureus infections.
Orphan disease is a fast growing market in the US, Europe and in particular China, where globally around 90% of identified 7000+ diseases are still lacking in effective treatment. The Smart-ActTM platform is our proprietary platform where we systematically screen over 1600+ small molecule FDA approved drugs against eventual 7000+ orphan diseases, including areas in oncology, genetic, immuno and metabolic diseases. Through our computational based screening, in-vitro/vivo validations and robust IP filtering, we target to systematically select and repurpose drug candidates (often with existing well established human safety and toxicity profiles and phase 1–3 data) and deliver a number of new phase 2/3 ready clinical stage assets each year going forward, across the orphan diseases spectrum.
SACT-1 is our first proof-of-concept asset developed under the Smart-ActTM platform targeting Neuroblastoma, a rare form of nerve tissue cancer predominantly in children, is undergoing excellent progress in its preclinical preparation and targeted in H2 2020 for IND submission under the US FDA 505B(2) pathway and China pathways, following which upon FDA approval, the confirmation stage clinical studies to commence swiftly thereafter. Further information of SACT-1 is available at our latest press release.
Our other lead candidate in infectious diseases, ALS-4 targeting S. aureus infections (including MRSA) is undergoing excellent IND enabling studies progress and is targeted in H2 2020 for IND submission for the US and China regulatory pathways to commence phase 1 clinical stage studies. The Acticule infectious diseases platform is a collaboration with the University of Hong Kong Microbiology team, which is an extremely reputable team within this field and also the team that is deeply involved in the recent Coronavirus investigations and vaccine development. Further information of ALS-4 is available at our latest press release.
On this note, I would like to say thank you for your continued support and if you have any questions or collaboration you would like to explore, please feel free to contact one of us. I hope to provide you again further updates in a few months time on our above endeavours.
Yours sincerely,
Ian Huen
Founder and Chief Executive Officer
Aptorum Group
[Nasdaq: APM]
CONTACT US
Address: 17/F, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong
Tel: +852 2117 6611 Fax: +852 2850 7286
Email: investor.relations@aptorumgroup.com
Official Website: http://www.aptorumgroup.com
Find Out more about AENCO:
✔Website: https://aencoin.com
✔Telegram: https://t.me/Aenco
✔ Instagram: instagram.com/aencoin/
✔LinkedIn: www.linkedin.com/company/Aenco
✔Twitter: https://twitter.com/Aencoin
✔Facebook: https://facebook.com/Aencoin
✔Discord: https://discord.gg/NXpFcKQ
✔YouTube: YouTube.Aencoin.com
✔Viber: Aenco Vietnam
✔Zalo: zalo.me/g/vvglmj886
